USPTO serial 77401634
GLENMARK THERAPEUTICS INC., USA
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- WATSON, JULIE A
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with GLENMARK THERAPEUTICS INC., USA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical anti-allergic preparations and substances; Pharmaceutical for the treatment of erectile dysfunction; Pharmaceutical preparation for the treatment of gout; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; Pharmaceutical preparations for skin care; Pharmaceutical preparations for the prevention and treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system, the genitourinary system; for the treatment of inflammatory disorders; for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, for the treatment of bacteria-based diseases, and for the treatment of diabetes, and anti-infective preparations, antiviral preparations, antibiotics, antifungal preparations and vaccines; Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for the treatment of heart rhythm disorders; Pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations for treating allergic rhinitis and asthma; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations for use in urology; Pharmaceutical preparations for wounds; Pharmaceutical preparations, namely, antidepressants; Pharmaceutical preparations, namely, appetite suppressants; Pharmaceutical preparations, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; Pharmaceutical preparations, namely, a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents; Pharmaceutical preparations, namely, anticoagulants; Pharmaceutical products and preparations against dry skin caused by pregnancy; Pharmaceutical products and preparations for chloasma; Pharmaceutical products and preparations for hydrating the skin during pregnancy; Pharmaceutical products and preparations for pregnancy blemishes; Pharmaceutical products and preparations for preventing skin blemishes during pregnancy; Pharmaceutical products and preparations to prevent stretch marks; Pharmaceutical products and preparations to prevent swelling in the legs; Pharmaceutical products for ophthalmological use; Pharmaceutical products for skin care for animals; Pharmaceutical products for the treatment of bone diseases; Pharmaceutical products for the treatment of joint disease; Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; Pharmaceutical products for treating respiratory diseases and asthma; Pharmaceutical skin lotions; Pharmaceutical solutions used in dialysis; Pharmaceuticals for the treatment of erectile dysfunction; Pharmaceuticals, namely, anti-infectives; Pharmaceuticals, namely, antihelmintics; Pharmaceuticals, namely, inducers of erections; Pharmaceuticals, namely, lipid lowering agents; Preparation for the relief of pain | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Glenmark Pharmaceuticals Inc., USA
- Other trademarks owned by Glenmark Pharmaceuticals Inc., USA
- Other trademarks owned by GLENMARK THERAPEUTICS INC., USA
- Other trademarks in Class 005
- Similar marks named GLENMARK THERAPEUTICS INC., USA
- Prosecution event MAB6 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| May 23, 2011 | MAB6 | ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| May 23, 2011 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Oct 28, 2010 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Oct 27, 2010 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Oct 26, 2010 | TPEX | SOU EXTENSION RECEIVED WITH TEAS PETITION | — |
| Oct 26, 2010 | PETG | PETITION TO REVIVE-GRANTED | — |
| Oct 26, 2010 | PROA | TEAS PETITION TO REVIVE RECEIVED | — |
| Oct 21, 2010 | EXT3 | SOU EXTENSION 3 FILED | — |
| May 21, 2010 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| May 20, 2010 | EX2G | SOU EXTENSION 2 GRANTED | — |
| May 19, 2010 | TPEX | SOU EXTENSION RECEIVED WITH TEAS PETITION | — |
| May 19, 2010 | PETG | PETITION TO REVIVE-GRANTED | — |
| May 19, 2010 | PROA | TEAS PETITION TO REVIVE RECEIVED | — |
| Apr 21, 2010 | EXT2 | SOU EXTENSION 2 FILED | — |
| Mar 3, 2010 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Mar 3, 2010 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Mar 1, 2010 | PGEX | PETITION GRANTED - EXTENSION REQUEST FILED | — |
| Feb 3, 2010 | PINM | INCOMPLETE PETITION NOTICE MAILED | — |
| Feb 2, 2010 | APET | ASSIGNED TO PETITION STAFF | — |
| Feb 1, 2010 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Dec 1, 2009 | PETR | PETITION TO REVIVE-RECEIVED | — |
| Dec 1, 2009 | TPEX | SOU EXTENSION RECEIVED WITH TEAS PETITION | — |
| Dec 1, 2009 | PETG | PETITION TO REVIVE-GRANTED | — |
| Dec 1, 2009 | PROA | TEAS PETITION TO REVIVE RECEIVED | — |
| Nov 23, 2009 | MAB6 | ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Nov 23, 2009 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Oct 21, 2009 | EXT1 | SOU EXTENSION 1 FILED | — |
| Apr 21, 2009 | NOAM | NOA MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Jan 27, 2009 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jan 7, 2009 | NPUB | NOTICE OF PUBLICATION | — |
| Dec 22, 2008 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Dec 16, 2008 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Dec 15, 2008 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 15, 2008 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 15, 2008 | ALIE | ASSIGNED TO LIE | — |
| Dec 1, 2008 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 2, 2008 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 2, 2008 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 2, 2008 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 2, 2008 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 26, 2008 | NWAP | NEW APPLICATION ENTERED | — |